Evidence map›Paper›PMID 39781617›Full record

ArticleHaematologica2025

Tyrosine kinase inhibitor discontinuation in nonallografted Philadelphia-positive acute lymphoblastic leukemia patients: a Campus ALL real-life study.

Matteo Dragani, Michela Ansuinelli, Cristina Papayannidis, Nicola Fracchiolla, Valeria Cardinali, Michele Cedrone, Fabio Guolo, Salvatore Perrone, Prassede Salutari, Elisabetta Todisco and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Haematologica, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Trial
  2. Article
  3. PersistentHemaSphere · 2026
    Article
  4. Article
  5. Review
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Matteo DraganiHematology and Cellular Therapy, IRCCS Ospedale Policlinico San Martino. matteoemidio.dragani@hsanmartino.it.
Michela AnsuinelliHematology, Department of Translational and Precision Medicine, Sapienza University of Rome.
Cristina PapayannidisIstituto di Ematologia "Seràgnoli", IRCCS Azienda Ospedaliero-Universitaria di Bologna.
Nicola FracchiollaHematology Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico di Milano, Milano.
Valeria CardinaliDipartimento di Medicina e Chirurgia, Università di Perugia, Ospedale "Santa Maria della Misericordia", Perugia.
Michele CedroneUOC Ematologia, Azienda Ospedaliera San Giovanni Addolorata.
Fabio GuoloClinic of Hematology, Department of Internal Medicine (DiMI), University of Genova.
Salvatore PerroneDepartment of Hematology, Polo Universitario Pontino, S.M. Goretti Hospital, Latina.
Prassede SalutariDepartment of Hematology, Ospedale Civile Spirito Santo, Pescara.
Elisabetta TodiscoOnco-Hematology Division, IEO, European Institute of Oncology IRCCS, Milan, Italy; Hematology Division, Busto Arsizio Hospital, ASST Valleolona, Varese.
Robin FoàHematology, Department of Translational and Precision Medicine, Sapienza University of Rome.
Sabina ChiarettiHematology, Department of Translational and Precision Medicine, Sapienza University of Rome.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Identifiers

PMID39781617
PMCPMC12050923

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.